about
Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsEuropean perspective on multiple myeloma treatment strategies in 2014Innovative agents in multiple myelomaPotent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaNovel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.New strategies in the treatment of multiple myeloma.Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin.GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.Profile of elotuzumab and its potential in the treatment of multiple myelomaThe development of potential antibody-based therapies for myelomaMonoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Novel Immunotherapies for Multiple Myeloma.N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.Progress and Paradigms in Multiple Myeloma.CD138 mediates selection of mature plasma cells by regulating their survival.Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
P2860
Q26822754-C870278A-959E-4EE9-97AC-BCC2A92E7C88Q27005966-23CB7C41-121B-4B87-9C5B-9AB78B1A4F7DQ27022493-194DA453-D2CC-49F8-A2A9-5E2E32CE93E0Q27700745-BA996AE2-5361-4FB6-9513-9C629802B3B7Q28066890-489A09CC-92D5-45B6-B6FF-E9A1C19A4453Q33621610-13B7C789-07D3-4E10-8A93-68E9E2DFFA0BQ33958520-3B2E8E1D-8138-401B-92BE-5536660DDE31Q34656161-3D1DDA12-8EB9-4724-9944-8FDDC16A532BQ35146307-85541447-FF07-49F1-8FD8-26A149817000Q35628678-66A035A5-D57C-440F-B706-E1EE65DE8B16Q35788245-2AA0B392-46A6-4BFE-999E-EA639CD79DECQ38090691-B5E74455-6D7C-4D7D-974D-C5F732270466Q38640444-80507ED4-4D23-454D-8136-0AA5C294538DQ39002186-D2385CD8-61B5-4A5F-BFD3-7050A323654EQ39070515-7D4B41D7-99FA-47B8-8137-15EFEACA705DQ39325995-B90B79DE-AF58-4997-A5E9-A61B83D3DB68Q40575818-CD8DD634-FF45-4B19-9D59-FA31A70EA9CCQ40602973-E5F6BD10-A0E8-453E-AFEF-BB84CEC88FD9Q44694137-C6EE5D28-379F-4AE2-ABA0-DBF59688E5B6Q47927555-B8255E06-0F4C-4848-91A4-32AF4016B432Q50061670-9D9F8461-E30A-4E7E-8B09-E5794CC1869BQ50765392-ABD0125C-668D-4BEE-A6EF-DBE9A6977726
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antibody-based therapies in multiple myeloma
@ast
Antibody-based therapies in multiple myeloma
@en
type
label
Antibody-based therapies in multiple myeloma
@ast
Antibody-based therapies in multiple myeloma
@en
prefLabel
Antibody-based therapies in multiple myeloma
@ast
Antibody-based therapies in multiple myeloma
@en
P2860
P356
P1433
P1476
Antibody-based therapies in multiple myeloma
@en
P2093
Kenneth C Anderson
Yu-Tzu Tai
P2860
P304
P356
10.1155/2011/924058
P577
2011-03-02T00:00:00Z